Sunday, September 13, 2026

“A New Era for Skin Treatments Has Arrived”: Wontech Unveils ‘Oligio XM’ for First Time

Wontech unveiled its new flagship Oligio XM, combining radiofrequency and high-intensity focused ultrasound technologies in a single device.

Russia’s True Intentions For North Korean Labor

Despite North Korea and Russia promising economic...

Lee, Trump Exchange Views on North Korea as G7 Summit Concludes European Tour

President Lee Jae-myung engaged in diplomatic talks at the G7 summit, emphasizing cooperation with major economies on North Korea issues.

Tag: Mounjaro

Unlocking the Future: How Genomic Testing Enhances GLP-1 Obesity Treatment for Asian Patients

NGeneBio is developing tests to identify which patients benefit from GLP-1 weight loss drugs like Wegovy and Mounjaro, assessing side effects.

Novo Nordisk vs Eli Lilly: Is Weight Loss Advertising Misleading?

Novo Nordisk sues Eli Lilly for misleading ads on obesity drugs, claiming false comparisons and seeking corrective action in court.

Teen Prescriptions for GLP-1 Obesity Drugs Surge in Korea, Raising Misuse Concerns

Surge in GLP-1 obesity treatment prescriptions among teens raises concerns over misuse and potential health risks.

Mounjaro prescriptions surge 12-fold in 8 months, surpassing 200,000 monthly for the first time

Mounjaro prescriptions surged over tenfold in eight months, raising concerns about access for patients with obesity amid rising cosmetic demand.

Why Are Weight-Loss Drugs So Much Pricier in South Korea?

South Korea faces high obesity treatment costs compared to China and Japan, with no insurance coverage, despite potential patent expirations.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Top News

- Our Sponsors Ad -

Follow us